Vanderbilt researchers have identified a new antibacterial mechanism that could inspire novel strategies for combating staph and other extracellular bacterial pathogens.

Researchers at Vanderbilt University Medical Center (VUMC) and the Baylor College of Medicine in Houston, Texas, have taken a big step toward developing targeted treatments and vaccines against a family of viruses that attacks the gastrointestinal tract.

“We are seeing a spike in respiratory illnesses, especially RSV (respiratory syncytial virus) and parainfluenza, which cause croup and bronchiolitis in young children and flu-like symptoms in older children and adults,” said James Antoon, MD, PhD, FAAP, assistant professor of Pediatrics at Children’s Hospital at Vanderbilt.

In HIV-positive individuals with diabetes, immune cells in fat are more proinflammatory and cytotoxic and may represent a therapeutic target for diabetes.

HIV-1, the virus that causes AIDS, exploits inositol phosphates in T cells to aid its own assembly and maturation — suggesting that targeting inositol phosphate binding could inhibit HIV-1 replication.

Understanding how bacteria evolve resistance to antibiotics and host stresses could guide the development of more effective antimicrobial therapeutics.

Vanderbilt University Medical Center scientists have identified a C. diff protein system that senses and captures heme (part of hemoglobin) to build a protective shield that fends off threats from our immune system and antibiotics.